Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration SILICON VALLEY, Calif., (September 20, 2022) – Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...
Predicine Liquid Biopsy NGS Assay Granted Breakthrough Device Designation by FDA
